地塞米松对肺炎支原体感染大鼠血清及肺泡灌洗液中IL-12、IL-13的影响

临床儿科杂志 ›› 2014, Vol. 32 ›› Issue (3): 265-270.

地塞米松对肺炎支原体感染大鼠血清及肺泡灌洗液中IL-12、IL-13的影响

王志华^*, 王玉水，刘艳

天津市南开医院儿科（天津　300100）

收稿日期:2013-07-19 出版日期:2014-03-15 发布日期:2014-03-15

Effects of dexamethasone on the levels of IL-12 and IL-13 in bronchoalveolar lavage fluid and serum in rats

WANG Zhihua, WANG Yushui, LIU Yan

(Department of Pediatrics, Tianjin Nankai Hospital, Tianjin 300100, China)

Received:2013-07-19 Online:2014-03-15 Published:2014-03-15

摘要/Abstract

摘要：

阿奇霉素组、地塞米松组、联合干预组和模型对照组，每组各25只。各组大鼠均予MP菌液（1×10⁶ CFU/ml）缓慢滴入大鼠鼻腔，共4 d，在最后1次接种后第2天开始干预。采用ELISA方法监测干预后第3、5、8天大鼠血清及BALF液IL-12、IL-13水平，并对肺组织炎症浸润程度进行评分。结果　在干预第3、5、8天，阿奇霉素组、地塞米松组、联合干预组及模型对照组肺组织病理评分比较差异均有统计学意义（F=8.71~20.11，P均<0.01），其中均以联合干预组评分最低。在干预第3、5、8天，四组间血清及BALF液中IL-12、IL-13水平比较差异均有统计学意义（F=9.52~143.47，P均<0.01）；其中干预第3天，联合干预组血清IL-12高于阿奇霉素组，而血清及BALF液IL-13均低于阿奇霉素组，差异均有统计学意义（P均<0.05）。结论　地塞米松可能协同阿奇霉素通过促进大鼠体内IL-12分泌和抑制IL-13表达，减轻肺组织炎症。

王志华, 王玉水，刘艳. 地塞米松对肺炎支原体感染大鼠血清及肺泡灌洗液中IL-12、IL-13的影响[J]. 临床儿科杂志, 2014, 32(3): 265-270.

WANG Zhihua,WANG Yushui,LIU Yan . Effects of dexamethasone on the levels of IL-12 and IL-13 in bronchoalveolar lavage fluid and serum in rats [J]. , 2014, 32(3): 265-270.

参考文献

[1] 马少杰，辛德莉. 肺炎支原体感染与支气管哮喘的关系 [J]. 实用儿科临床杂志，2007，22(4)：35-37.
[2] Kosugi Y，Katsura H. A case of fulminant Mycoplasma pneumoniae pneumonia despite adequate antibiotic treatment [J]. Nihon Kokyuki Gakkai Zasshi，2009，47(6)：471-475.
[3] Lu A，Wang L，Zhang X，et al. Combined treatment for child refractory Mycoplasma pneumoniae pneumonia with ciprofloxacin and glucocorticoid [J]. Pediatr Pulmonol，2011，46(11)：1093-1097.
[4] Cimolai N，Taylor GP，Mah D，et al. Definition and application of a histopathological scoring scheme for an animal model of acute Mycoplasma pneumoniae pulmonary infection [J]. Microbiol Immunol，1992，36(5)：465-478.
[5] 刘晓红，辛德莉，侯安存，等. 小鼠肺炎支原体肺炎模型的建立及组织病理学评分方法的应用 [J]. 重庆医学，2004，33(9)：1338-1340.
[6] 王芬，耿荣，钱素云，等．152例社区获得性肺炎住院患儿的病原学分析 [J]．中华急诊医学杂志，2011，20(8)：866-868.
[7] Tanaka H，Narita M，Teramoto S，et al. Role of interleukin-18 and T-helper type 1 cytokines in the development of Mycoplasma pneumoniae pneumonia in adults [J]. Chest，2002，121(5)：1493-1497.
[8] Lee KY，Lee HS，Hong JH，et al. Role of prednisolone treatment in severe Mycoplasma pneumoniae pneumonia in children [J]. Pediatr Pulmonol，2006，41(3)：263-268.
[9] Miyashita N，Obase Y，Ouchi K，et al. Clinical features of severe Mycoplasma pneumoniae pneumonia in adults admitted to an intensive care unit [J]. J Med Microbiol，2007，56(Pt 12):1625-1629.
[10] Cimolai N. Corticosteroids and complicated Mycoplasma pneumoniae infection [J]. Pediatr Pulmonol，2006，41(10)：1008-1009.
[11] Chu HW，Campbell JA，Rino JG，et al. Inhaled fluticasone propionate reduces concentration of Mycoplasma pneumoniae, inflammation，and bronchial hyperresponsiveness in lungs of mice [J]. J Infect Dis，2004，189(6)：1119-1127.
[12] Koh YY，Park Y，Lee HJ，et al. Levels of interleukin-2，interferon-gamma，and interleukin-4 in bronchoalveolar lavage fluid from patients with mycoplasma pneumonia：implication of tendency toward increased immunoglobulin E production [J]. Pediatrics，2001 ，107( 3)：E39.
[13] Trinchieri G. Biological properties and therapeutic applications of interleukin-12 [J]. Eur Cytokine Netw，1997，8(3)：305-307.
[14] Hardy RD，Jafri HS，Olsen K，et al. Elevated cytokine and chemokine levels and prolonged pulmonary air flow resistance in a murine Mycoplasma pneumoniae pneumonia model：a microbiologic histologic immunologic and respiratory plethysmographic profile [J]. Infect Immun，2001，69(6)：3869-3876.
[15] Dakhama A，Park JW，Taube C，et al. The enhancement or prevention of airway hyperresponsiveness during reinfection with respiratory syncytial virus is critically dependent on the age at first infection and IL-13 production [J]. J Immunol，2005，175(3):1876-1883.
[16] Tekkanat KK，Maassab H，Berlin AA，et al. Role of interleukin-12 and Stat-4 in the regulation of airway inflammation and hyperreactivity in respiratory syncytial virus infection [J]. Am J Pathol，2001，159(2)：631-638.
[17] Remmelts HH，Meijvis SC，Biesma DH，et al. Dexamethasone downregulates the systemic cytokine response in patients with community-acquired pneumonia [J]. Clin Vaccine Immunol，2012，19(9):1532-1538.